低分子肝素预防妇科肿瘤下肢深静脉血栓的临床应用研究.docVIP

低分子肝素预防妇科肿瘤下肢深静脉血栓的临床应用研究 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：低分子肝素预防妇科肿瘤下肢深静脉血栓的临床应用研究 1 1 资料与方法 3 2 结果 4 3 讨论 4 文2：低分子肝素配合医用弹力袜预防全髋关节置换术后下肢深静脉血栓的 6 1 资料与方法 6 2 结果 8 3 讨论 8 参考文摘引言： 9 原创性声明（模板） 10 文章致谢（模板） 10 正文 低分子肝素预防妇科肿瘤下肢深静脉血栓的临床应用研究 文1：低分子肝素预防妇科肿瘤下肢深静脉血栓的临床应用研究 【Abstract】 Objective to study the feasibility of low moleculer weight hesparin (LMWH) used to prevent vein thrombosis of patients after gynecological tumour surgery. Methods 246 patients with high risk facto to thrombopoiesis were studied. 123 patients in treated group were treated with LMWH and 123 patients in un-treated group were not treated with LMWH. The rate of postoperative hemorrhage , deep vein thrombosis(DVT) and pulmonary embolism(PE) were compared between two groups. The change of D-dimer, Fbg, PT and PLT of patients in treated group were analyzed at the third day after LMWT application. Result The rate of DVT and PE in treated group was lower than that in un-treatde group(p＜), There was no significant difference in the rate of postoperative hemorrhage between treated group and un-treated group(P). D-dimer and Fbg decreased significantly (P＜) at the third day after LMWT application, PT and PLT had no significant change(P). Conclusion: LMWH can be used safely and effectively in prevention and cure deep vein thrombosis of patients after gynecological surgery. 【Key words】Low moleculer weight hesparin(LMWH) gynecological tumour deep vein thrombosis Fbg D-dimer 下肢深静脉血栓（DVT）是在某些情况下，血液与静脉腔内凝结并阻塞静脉腔，导致静脉回流障碍引起血栓远端静脉高压和肢体肿胀、疼痛及浅静脉扩张等临床症状。早在19世纪中期，Virchow就提出了血液缓慢、血液高凝状态及静脉内膜损伤是下肢静脉血栓形成三大因素，至今这个理论仍受到普遍的公认。[1]盆腔恶性肿瘤患者由于癌细胞可分泌类组织因子和促凝物质，术后更容易发生静脉血栓。文献报道晚期卵巢癌和外阴癌术后约45%发生静脉血栓形成。因此，早期识别妇科肿瘤围手术期血栓前状态，及时应用有效药物进行防治，预防妇科肿瘤术后DVT的发生，对降低肺栓塞（FE）的发生率，降低肿瘤患者的致残率、死亡率具有极其重要的意义。本研究通过对具有血栓形成危险因素的患者预防应用低分子肝素进行治疗，旨在为妇科肿瘤术后静脉血栓形成的防治提供一些依据。 1 资料与方法 对象与分组 选自2006年6月—2008年6月在我院妇产科住院的具有高危因素的246例妇科肿瘤患者作为研究对象，高危因素包括遗传性血栓形成倾向，恶性肿瘤、老年妇女血液粘稠度高、高血压、糖尿病，肥胖、下肢静脉曲张等。年龄为49-72岁，平均岁。根据知情同意自愿的原则分为两组，接受低分肝